Brokerages Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) PT at $11.67

Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) have been assigned an average rating of “Moderate Buy” from the five analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $11.6667.

Separately, Weiss Ratings raised Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th.

Institutional Investors Weigh In On Acrivon Therapeutics

Several large investors have recently bought and sold shares of the company. Invesco Ltd. acquired a new stake in Acrivon Therapeutics in the first quarter worth $72,000. XTX Topco Ltd acquired a new position in shares of Acrivon Therapeutics in the 2nd quarter valued at $126,000. Jane Street Group LLC bought a new stake in shares of Acrivon Therapeutics in the 2nd quarter valued at $371,000. UBS Group AG raised its stake in Acrivon Therapeutics by 150,057.8% during the 3rd quarter. UBS Group AG now owns 683,218 shares of the company’s stock worth $1,237,000 after buying an additional 682,763 shares during the period. Finally, Two Sigma Investments LP lifted its holdings in Acrivon Therapeutics by 76.2% during the third quarter. Two Sigma Investments LP now owns 319,205 shares of the company’s stock worth $578,000 after acquiring an additional 138,033 shares in the last quarter. Institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Stock Up 6.3%

NASDAQ:ACRV opened at $1.52 on Friday. Acrivon Therapeutics has a 12-month low of $1.20 and a 12-month high of $3.56. The stock’s fifty day simple moving average is $1.66 and its 200-day simple moving average is $1.69. The firm has a market capitalization of $65.06 million, a P/E ratio of -0.76 and a beta of 1.82.

Acrivon Therapeutics (NASDAQ:ACRV) last released its earnings results on Wednesday, May 13th. The company reported ($0.49) earnings per share for the quarter, meeting the consensus estimate of ($0.49). As a group, equities research analysts expect that Acrivon Therapeutics will post -1.92 earnings per share for the current year.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.